Live RSS
Federal Grant · National Institutes of Health

Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)

Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.

BiotechHealthcare Tech small-teamuniversity-researchersmall-business
The pitch

If you have preliminary evidence linking patient biology to probiotic response variability, NIH will fund you to prove causality and build predictive models—with optional clinical validation.

Award range
Unspecified
Closes
Jun 2, 2027 · 399d left
Open date
Oct 31, 2024
Difficulty
High
Source
Grants.gov
Agency
National Institutes of Health
Last verified
2026-04-29
Fit language
Possible fit only
Apply at grants.gov →

Report stale or inaccurate summary

What this is

This R33 mechanism funds research advancing precision probiotic therapies by characterizing person-specific biological features that determine probiotic treatment success. Applicants must have preliminary data showing potential host factors (microbiome composition, genetics, immune markers, lifestyle) correlate with probiotic response, then conduct rigorous mechanistic studies in animal models or human subjects to establish causality and predictive value. The goal is solving the heterogeneity problem—why some people respond well to probiotics while others don't—through systems-level biology. This is a later-stage grant (R33), ideal for teams with foundational evidence seeking to validate mechanisms.

Who can apply

Broad eligibility including small businesses, nonprofits with or without 501(c)(3) status, universities, government entities, and tribal organizations. No geographic restriction. For-profit companies are eligible but primarily targeted at research-focused organizations with capacity for mechanistic studies.

Eligible applicant types

Full description — from the agency

The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate precision probiotic interventions. Specifically, this NOFO solicits R33 applications that will characterize person-specific features affecting probiotic responses to identify subgroups of probiotic responders and to enhance probiotic clinical outcomes. The ultimate goal of this NOFO is to identify, understand, and develop strategies to address barriers in precision probiotic therapies to account for the heterogenicity in humans that causes inconsistent probiotic responses. This NOFO will support studies to assess the ability of the unique patterns of host biology (e.g., native microbiome, immune system, gender, diet, age, genetic background, lifestyle, and health history) that are correlated with probiotic usage to detect the improvement of probiotic responsiveness. Well-suited applications must offer rigorously designed mechanistic studies using relevant/innovative animal models or in human subjects. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage have been identified, as demonstrated with supportive preliminary data, but require further mechanistic studies to test for their causality or predictability. Applicants pursuing early-stage research to identify host biological patterns that may affect probiotic health outcomes should consider the companion (R61/R33) NOFO PAR-AT-24-XXX (TEMP-25412).

Topics: precision probiotics · mechanistic research · host microbiome · probiotic response prediction · personalized medicine · clinical trial optional

Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.